30398 
Federal Register / Vol. 56, No. 127 / Tuesday, July 2, 1991 / Notices 
specific incidence rates of Alzheimer's 
disease, and (3) to foster research on 
selective risk factors and protective 
factors for Alzheimer’s disease — the 
purpose is no less than to hasten the 
search for the cause(s). 
For additional information, please 
contact; Ms. Chally L. Tate, 
Neuroscience and Neuropsychology of 
Aging Program, National Institute on 
Aging, National Institutes of Health, 
Building 31, room 5C35, 9000 Rockville 
Pike, Bethesda, Maryland 20892, 
Telephone: (301) 496-9350, FAX: (301) 
496-1494. 
Dated; June 26, 1991. 
Bemadine Healy, 
Director, National Institutes of Health. 
(FR Doc. 91-15777 Filed 7-1-91; 8:45 am] 
BILLING CODE 4140-01-M 
Human Gene Therapy Subcommittee; 
Meeting 
Pursuant to Public Law 92-463, notice 
is hereby given of a meeting of the 
Human Gene Therapy Subcommittee (a 
subcommittee of the Recombinant DNA 
Advisory Committee) on July 29-30, 
1991, The meeting will be held at the 
National Institutes of Health (NIH), 
Building 31, Conference Room 6, 9000 
Rockville Pike, Bethesda, Maryland 
20892, starting on July 29 at 
approximately 9 a.m. to adjournment on 
July 30 at approximately 5 p.m. 
The meeting will be open to the public 
to discuss the following proposed 
actions under the NIH Guidelines for 
Research Involving Recombinant DNA 
Molecules (51 FR 16958); 
I. Addition to Appendix D of the “NIH 
Guidelines" Regarding a Human Gene 
Transfer Protocol/Dr. Freeman 
In a letter dated May 10, 1991, Dr. 
Scott M. Freeman of the University of 
Rochester School of Medicine indicated 
his intention to submit a human gene 
transfer protocol to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA A»dvisory Committee 
for formal review and approval. The title 
of this protocol is: “Gene Transfer for 
the Treatment of Cancer." 
IL Addition to Appendix D of the “NIH 
Guidelines” Regarding a Human Gene 
Therapy Protocol/Dr. Lotze 
In a letter dated June 4, 1991, Dr. 
Michael T. Lotze of the University of 
Pittsburgh School of Medicine indicated 
his intention to submit a human gene 
therapy protocol to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA Advisory Committee 
for formal review and approval. The title 
of this protocol is: “Immunization of 
Cancer Patients with Autologous Tumor 
Transduced with IL-2 Retroviral 
Vectors: In Vivo Sensitivity to Tumor 
Antigens (VISTA)." 
III. Additions to Appendix D of the “NIH 
Guidelines" Regarding Human Gene 
Therapy Protocols/Dr. Rosenberg 
In a letter dated June 6, 1991, Dr. 
Steven A. Rosenberg of the National 
Institutes of Health indicated his 
intention to submit two human gene 
therapy protocols to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA Advisory Committee 
for formal review and approval. 
The first protocol is entitled: 
“Immunization of Cancer Patients Using 
Autologous Cancer Cells Modified by 
Insertion of the Gene for Tumor 
Necrosis Factor.” 
The second protocol is entit'ed: 
“Immunization of Cancer Patients Using 
Autologous Cancer Cells Modified by 
Insertion of the Gene for Interleukin-2.” 
IV. Addition to Appendix D of the “NIH 
Guidelines” Regarding a Human Gene 
Therapy Protocol/ Dr. Wilson 
In a letter dated June 7, 1991, Dr. 
James M. W'ilson of the University of 
Michigan Medical Center indicated his 
intention to submit a human gene 
therapy protocol to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA Advisory Committee 
for formal review and approval The title 
of this protocol is: “Gene Therapy of 
Familial Hypercholesterolemia.” 
V. Addition to Appendix D of the “NIH 
Guidelines” Regarding a Human Gene 
Therapy Protocol/Dr. Nabel 
In a letter dated June 7, 1991, Dr. Gary 
j. Nabel of the University of Michigan 
Medical Center indicated his intention 
to submit a human gene therapy 
protocol to the Human Gene Therapy 
Subcommittee and the Recombinant 
DNA Advisory Committee for formal 
review and approval. The title of this 
protocol is: “Gene Therapy as Related to 
the Immunotherapy of Cancer.” 
V. Other Matters To Be Considered by 
the Committee, 
Protocols which are approved by the 
Human Gene Therapy Subcommittee 
will be forwarded to the Recombinant 
DNA Advisory Committee for 
consideration during their October 7-8. 
1991, meeting. 
Attendance by the public will be 
limited to space available. Members of 
the public wishing to speak at this 
meeting may be given such opportunity 
at the discretion of the Chair. 
Dr. Nelson A. Wivel, Director, Office 
of Recombinant DNA Activities, 
National Institutes of Health, Building 
31, room 4B11, Bethesda, Maryland 
20892, telephone (301) 496-9838, fax (301) 
496-9839, wiU provide materials to be 
discussed at this meeting, roster of 
committee members, and substantive 
program information. A summary of the 
meeting will be available at a later date. 
O.MB's “Mandatory Information 
Requirements for Federal Assistance 
Program Announcements" (45 FR 39592, 
June 1, 1980) requires a statement 
concerning the official government 
programs contained in the Catalog of 
Federal Domestic Assistance. Normally 
NIH lists in its announcements the 
number and title of affected individual 
programs for the guidance of the public. 
Because the guidance in this notice 
covers not only virtually every NIH 
program but also essentially every 
Federal research program in which DNA 
recombinant molecule techniques could 
be used, it has been determined not to 
be cost effective or in the public interest 
to attempt to list these programs. Such a 
list would likely require several 
additional pages. In addition, NIH could 
not be certain that every Federal 
program would be included as many 
Federal agencies, as well as private 
organizations, both national and 
international, have elected to follow the 
AT// Guidelines. In lieu of the individual 
program listing, NIH invites readers to 
direct questions to the information 
address above about whether individual 
programs listed in the Catalog of 
Federal Domestic Assistance are 
affected. 
Dated: June 25. 1991. 
Betty J. Beveridge, 
Committee Management Officer. NIH. 
(FR Doc. 91-15663 Filed 7-1-91: 8:45 am] 
BILUNQ CODE 4140-01-M 
DEPARTMENT OF THE INTERIOR 
Bureau of Land Management 
[UT-920-91-4120-10] 
Utah and Colorado: Uinta 
Southwestern Utah Regional Coal 
Team Meeting 
AGENCY: Bureau of Land Management. 
Interior. 
ACTION: Notice of regional coal team 
meeting. 
SUMMARY: In accordance with the 
responsibility outlined in the Federal 
Coal Management Regulations (43 CFR 
part 3400), the Regional Coal Team 
(ROT) for the presently decertified Uinta 
Southwestern Utah Federal Coal 
[ 866 ] 
Recombinant DNA Research, Volume 14 
